Potential Biomarkers of Immunotherapy in NSCLC
Comprehensive Genomic Profiling (CGP) Uncovered Potential Biomarkers of Immunotherapy in NSCLC – Good Predictive Markers: TMB-H, BRAF and MET; Poor Predictive Marker: STK11 [1138PD]
Primary results of LORELEI
Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal patients with ER+/HER2-negative early breast cancer (EBC)[LBA10_PR]
Alectinib vs Crizotinib in Treatment-Naive ALK+ NSCLC
Alectinib vs Crizotinib in Treatment-Naive ALK+ NSCLC: CNS Efficacy Result From The ALEX Study [1298O_PR]
Blood-based comprehensive genomic profiling (CGP)
Blood-based comprehensive genomic profiling (CGP) assay may tackle the significant challenges in NSCLC management, 1) insufficient tumor tissue for molecular testing; 2) complexity of genotype related treatment decision, see bTMB and BFAST [102P]
Clinical efficacy of atezolizumab
Clinical efficacy of atezolizumab in PD-L1 selected subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: results from the randomized OAK trial [1296O], Shirish Gadgeel, et al